Bristol-Myers' (BMY) Lack of Suitor Positive for Celgene (CELG) Deal - Baird

March 12, 2019 1:34 PM
Baird analyst Brian Skorney reiterated an Outperform rating and $101.00 price target on Celgene (NASDAQ: CELG), saying they are positive ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Mergers and Acquisitions Rumors

Next Articles